Biomerieux, Inc.

Institut National De La Sante Et De La Recherche Medicale

Frederic Bedin

Bernard F Mandrand

Herve Perron

Frederic Beseme

Francois Mallet

Glaucia Paranhos-Baccala

Florence Komurian-Pradel

Colette Jolivet-Reynaud

Mireille Sodoyer

Catherine Ott

Christian G Trepo

Sandrine Busseret

Jeremy Alexander Garson

Isabelle Chemin

Philip William Tuke

Marine Steidel

Colette Jolivet Reynaud

A kit for in vitro prediction of severe dengue includes a binding partner specific for leucine-rich alpha-2 glycoprotein, a binding partner specific for vitamin D-binding protein, and a binding partner specific for ferritin. The kit may further include at least one binding partner specific for a dengue virus protein wherein the dengue virus protein is the NS1 protein, the envelope protein, or the prM protein.

Method for the in vitro prediction of the probability of a patient developing severe dengue, based on a blood sample

Disclosed is a process for in vitro detection of an infection by a dengue virus in an individual, including the following steps: contacting a blood sample from the individual with a ligand specific to the NS1 protein of said dengue virus, to capture NS1 protein if it is present in the blood sample, said ligand being immobilized on a solid support; detecting the presence of NS1 protein via a mass spectrometry reading; and if NS1 protein is detected, concluding that the individual has been infected by dengue virus.

Process for the detection and early serotyping of the dengue virus

An isolated polynucleotide having a nucleotide sequence selected from the group consisting of (a) SEQ ID NO: 21, (b) the full-length sequences encoding a polypeptide having a peptide sequence selected from the group consisting of SEQ ID NOs: 25 and 26, and (c) the full-length complementary sequences to the sequences set forth in (a) or (b).

Isolated multiple sclerosis (MS)-associated retrovirus (MSRV) nucleic acids corresponding to the gag region

Viral material, in the isolated or purified state, in which the genome comprises a nucleotide sequence chosen from the group including sequences SEQ ID NO:46, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53 and SEQ ID NO:56, their complementary sequences and their equivalent sequences, in particular nucleotide sequences displaying, for any succession of 100 contiguous monomers, at least 50% and preferably at least 70% homology with the said sequences SEQ ID NO:46, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53 and SEQ ID NO:56, respectively, and their complementary sequences.

Viral material and nucleotide fragments associated with multiple sclerosis, for diagnostic, prophylactic and therapeutic purposes

The invention concerns a nucleic material, in isolated or purified state, and a nucleotide fragment comprising a nucleotide sequence selected from the group consisting in (i) the sequences SEQ ID NO: 112, SEQ ID NO:114, SEQ ID NO: 117, SEQ ID NO: 120, SEQ ID NO. 124, SEQ ID NO: 130, SEQ ID NO: 141 and SEQ ID NO: 142, (ii) the complementary sequences of sequences (i); and (iii) the sequences equivalent to sequences (ii) and (iii), in particular the sequence having for every series of 100 contiguous monomers, at least 50%, preferably 70% homology with sequences (i) and (ii) respectively. The invention also concerns their uses for detecting a retrovirus associated with multiple sclerosis and/or rheumatoid arthritis.

Multiple sclerosis-associated retroviral (MSRV) nucleic acids corresponding to the Env region

The invention provides viral material and nucleotide fragments associated with multiple sclerosis and/or rheumatoid arthritis for use in method of diagnosis, prophylaxis, and therapy.

Isolated HXHV virus having the following characteristics:

HXHV virus, nucleic material, peptide material and uses

The invention provides viral material and nucleotide fragments associated with multiple sclerosis and/or rheumatoid arthritis for use in methods of diagnosis, prophylaxis, and therapy.

Isolated nucleotide sequences associated with multiple sclerosis or rheumatoid arthritis and a process of detecting

Composition comprising two pathogenic and/or infective agents associated with multiple sclerosis, namely a first agent which consists of a human virus possessing reverse transcriptase activity and related to a family of endogenous retroviral elements, or a variant of said virus, and a second agent, or a variant of said second agent, these two pathogenic and/or infective agents originating from the same viral strain chosen from the strains designated, respectively, POL-2 deposited with the ECACC on Jul. 22 1992 under Accession Number V92072202 and MS7PG deposited with the ECACC on Jan. 8 1993 under Accession Number V93010816, and from their variant strains.

Cell lines and viral isolates associated with multiple sclerosis

Composition comprising two pathogenic and/or infective agents associated with multiple sclerosis, namely a first agent which consists of a human virus possessing reverse transcriptase activity and related to a family of endogenous retroviral elements, or a variant of said virus, and a second agent, or a variant of said second agent, these two pathogenic and/or infective agents originating from the same viral strain chosen from the strains designated, respectively, POL-2 deposited with the ECACC on Jul. 22, 1992 under Accession Number V92072202 and MS7PG deposited with the ECACC on Jan. 8, 1993 under Accession Number V93010816, and from their variant strains.

Viral isolates associated with multiple sclerosis

Isolated nucleotide sequences associated with Multiple sclerosis

Composition including two pathogenic and/or infective agents associated with multiple sclerosis, namely a first agent which consists of a human virus possessing reverse transcriptase activity and related to a family of endogenous retroviral elements, or a variant of the virus, and a second agent, or a variant of the second agent, these two pathogenic and/or infective agents originating from the same viral strain chosen from the strains designated, respectively, POL-2 deposited with the ECACC on Jul. 22, 1992 under Accession Number V92072202 and MS7PG deposited with the ECACC on Jan. 8, 1993 under Accession Number V93010816, and from their variant strains.

Growing community of inventors

Lyons, France

Frederic Bedin